Interim effect evaluation of the hepatitis C elimination programme in Georgia: a modelling study. Issue 2 (February 2020)

• Record Type: Journal Article
• Authors: Walker, Josephine G; Kuchuloria, Tinatin; Sergeenko, David; Fraser, Hannah; Lim, Aaron G; Shadaker, Shaun; Hagan, Liesl; Gamkrelidze, Amiran; Kvaratskhelia, Valeri; Gvinjilia, Lia; Aladashvili, Malvina; Asatiani, Alexander; Baliashvili, Davit; Butsashvili, Maia; Chikovani, Ivdity; Khonelidze, Irma; Kirtadze, Irma; Kuniholm, Mark H; Otiashvili, David; Sharvadze, Lali; Stvilia, Ketevan; Tsertsvadze, Tengiz; Zakalashvili, Mamuka; Hickman, Matthew; Martin, Natasha K; Morgan, Juliette; Nasrullah, Muazzam; Averhoff, Francisco; Vickerman, Peter
• Is Part Of: Lancet. Volume 8:Issue 2(2020)
• Page Start: e244
• Page End: e253
• Publication Date: 2020-02
• Subjects: World health -- Periodicals; 362.105
• DOI: 10.1016/S2214-109X(19)30483-8
• Languages: English
• ISSNs: 2214-109X

Abstract

Summary: Background: Georgia has a high prevalence of hepatitis C, with 5·4% of adults chronically infected. On April 28, 2015, Georgia launched a national programme to eliminate hepatitis C by 2020 (90% reduction in prevalence) through scaled-up treatment and prevention interventions. We evaluated the interim effect of the programme and feasibility of achieving the elimination goal. Methods: We developed a transmission model to capture the hepatitis C epidemic in Georgia, calibrated to data from biobehavioural surveys of people who inject drugs (PWID; 1998–2015) and a national survey (2015). We projected the effect of the administration of direct-acting antiviral treatments until Feb 28, 2019, and the effect of continuing current treatment rates until the end of 2020. Effect was estimated in terms of the relative decrease in hepatitis C incidence, prevalence, and mortality relative to 2015 and of the deaths and infections averted compared with a counterfactual of no treatment over the study period. We also estimated treatment rates needed to reach Georgia's elimination target. Findings: From May 1, 2015, to Feb 28, 2019, 54 313 patients were treated, with approximately 1000 patients treated per month since mid 2017. Compared with 2015, our model projects that these treatments have reduced the prevalence of adult chronic hepatitis C by a median 37% (95% credible interval 30–44), the incidence of chronic hepatitis C by 37% (29–44), and chronic hepatitis C mortality by 14% (3–30) and have prevented 3516 (1842–6250) new infections and averted 252 (134–389) deaths related to chronic hepatitis C. Continuing treatment of 1000 patients per month is predicted to reduce prevalence by 51% (42–61) and incidence by 51% (40–62), by the end of 2020. To reach a 90% reduction by 2020, treatment rates must increase to 4144 (2963–5322) patients initiating treatment per month. Interpretation: Georgia's hepatitis C elimination programme has achieved substantial treatment scale-up, which has reduced the burden of chronic hepatitis C. However, the country is unlikely to meet its 2020 elimination target unless treatment scales up considerably. Funding: CDC Foundation, National Institute for Health Research, National Institutes of Health.